{"transactions":[{"id":2534301,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":134208,"kind":"person","name":"Merck KGaA","position":1,"cik":"0001764133","reported_name":"Merck KGaA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Srock","published_at":"2021-10-26T21:06:33.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":2515271,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":264765},"source":{"system":"sec-edgar","filing":"0001104659-21-130030","document":"tm2130646-26_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764133/000110465921130030/tm2130646-26_4seq1.xml","form_type":"4"}},{"id":2534300,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":134208,"kind":"person","name":"Merck KGaA","position":1,"cik":"0001764133","reported_name":"Merck KGaA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-10-26T21:06:33.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":3952568,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":416060},"source":{"system":"sec-edgar","filing":"0001104659-21-130030","document":"tm2130646-26_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764133/000110465921130030/tm2130646-26_4seq1.xml","form_type":"4"}},{"id":2534299,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":134208,"kind":"person","name":"Merck KGaA","position":1,"cik":"0001764133","reported_name":"Merck KGaA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-26T21:06:33.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":264765,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V."}],"balance_after":680825,"source":{"system":"sec-edgar","filing":"0001104659-21-130030","document":"tm2130646-26_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764133/000110465921130030/tm2130646-26_4seq1.xml","form_type":"4"}},{"id":2534298,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":134208,"kind":"person","name":"Merck KGaA","position":1,"cik":"0001764133","reported_name":"Merck KGaA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-26T21:06:33.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":416060,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V."}],"balance_after":416060,"source":{"system":"sec-edgar","filing":"0001104659-21-130030","document":"tm2130646-26_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764133/000110465921130030/tm2130646-26_4seq1.xml","form_type":"4"}}]}